"Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.These changes and more are addressed in Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:Histology/CytologyImmunoassaysFlow CytometryRapid TestsMolecular AssaysTissue ArraysCirculating Tumor CellsPharmacodiagnosticsDiagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease.Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:Immunoassay Lab Based Cancer Test Sales Pap Smear Testing VolumesWorld Cancer Statistics POC Tests DNA Reagents for Cancer TestingCTC Testing Markets Biochip Innovations New Companies with Novel Approaches ""Laggard"" Companies Who Have Not Met ExpectationsMajor Protein and Molecular Markers Used in Tissue StainingBiomarkers Under Investigation Acquisitions and Mergers Status of PGx TestingMicroarray Markets in Clinical LabsLists of Vendors and Major Products Unmet Needs of the Marketplace This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISHAs well as tests for specific cancers:Bladder Cancer Breast Cancer Cervical Cancer Colon Cancer Lung Cancer Ovarian Cancer Prostate CancerThis latest edition of Kalorama Information's study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways: Tests for specific cancers, and Cancer tests in specific IVD segments This allows the reader to match his or her own situation to the market at large.In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles.Top Tier Companies Abbott Diagnostics Beckman Coulter Inc. Becton, Dickinson and Company (BD) bioMerieux Inc. Bio-Rad Laboratories Inc. Dako A/S Fujirebio Diagnostics, Inc. Gen-Probe Inc. Hologic, Inc. Inverness Medical Innovations Ortho Clinical Diagnostics QIAGEN N.V. Roche DiagnosticsSiemens Medical Solutions Diagnostics Sysmex Corporation Status Quo Leader Companies AdnaGen AG Agendia BV AMDL Diagnostics, Inc. (ADI) American Diagnostica Inc. Aperio Technologies, Inc. Asuragen, Inc. AviaraDx Binding Site (The) Ltd. BioCurex Inc. BioGenex Laboratories, Inc. BioImagene Bio-Reference Laboratories, Inc. Biotage AB bioTheranostics BioView Ltd. Celera Diagnostics China Medical Technologies, Inc. Cisbio Bioassays Clarient Inc. (formerly ChromaVision) Clinical Data, Inc. CytoCore, Inc. DxS Ltd. Epigenomics AG Genetix Applied Imaging Genomic Health, Inc. Genzyme Genetics Health Discovery Corporation HistoRx, Inc. Ikonisys, Inc. Ipsogen SA Lab21 Healthcare Laboratory Corporation of America Holdings (LabCorp) Life Technologies Monogram Biosciences, Inc. mtm laboratories AG Myriad Genetics, Inc. Nanosphere, Inc. OncoVista Innovative Therapies, Inc. Pathwork Diagnostics Precision Therapeutics Prometheus Laboratories Inc. Q
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
This document provides a summary and table of contents of the "World Biomass Report" published in November 2012. The report examines the global biomass market and finds that while it suffered during the economic downturn due to low coal prices and supply issues, the sector began growing again in 2010 as coal prices rose. Most biomass plants rely on wood pellets imported from North America, though suppliers from other regions like Russia and Australia aim to compete in the market. The full report contains detailed information on biomass resources, technologies, logistics, investments and policies on a global and national level.
This report provides an overview of the global biofuels industry in 2012. It summarizes production and policies related to first, second, and third generation biofuels in countries around the world. The report finds that 2009 was a difficult year for the biofuels industry due to low oil prices and reduced demand. However, projects using diverse feedstocks or next generation technologies like cellulosics and algae continued to receive investment. The report includes sections on biofuel production trends, technologies, environmental impacts, and policies in regions like Europe, the USA, and individual European countries.
This report analyzes the current state of various renewable energy technologies including hydropower, wind, solar, biomass, biofuels, and geothermal. It examines the market size and outlook for each technology by region, discusses the advantages and disadvantages of different renewable sources, and assesses the development status and future potential of the renewable energy industry globally. The report also profiles major renewable energy companies and evaluates government policies and industry support programs around the world.
This report provides an overview of the global solar photovoltaic (PV) market. It outlines key industry data like global solar capacity, production figures, and forecasts for future growth. It also examines major country markets and discusses the advantages, challenges, and components of the solar PV industry. The report analyzes factors such as government incentives, technology developments, and manufacturing trends that are shaping the future of the solar industry.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report from GlobalData on clinical trials for abdominal aortic aneurysms. The report provides data on over 100 clinical trials conducted between 2007-2012, including regional breakdown of trials, top sponsoring companies and universities, prominent drugs being tested, and trends in trial enrollment numbers over time. The report aims to give readers an overview of experimental treatments and global research activity for abdominal aortic aneurysms.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
This document provides a summary and table of contents of the "World Biomass Report" published in November 2012. The report examines the global biomass market and finds that while it suffered during the economic downturn due to low coal prices and supply issues, the sector began growing again in 2010 as coal prices rose. Most biomass plants rely on wood pellets imported from North America, though suppliers from other regions like Russia and Australia aim to compete in the market. The full report contains detailed information on biomass resources, technologies, logistics, investments and policies on a global and national level.
This report provides an overview of the global biofuels industry in 2012. It summarizes production and policies related to first, second, and third generation biofuels in countries around the world. The report finds that 2009 was a difficult year for the biofuels industry due to low oil prices and reduced demand. However, projects using diverse feedstocks or next generation technologies like cellulosics and algae continued to receive investment. The report includes sections on biofuel production trends, technologies, environmental impacts, and policies in regions like Europe, the USA, and individual European countries.
This report analyzes the current state of various renewable energy technologies including hydropower, wind, solar, biomass, biofuels, and geothermal. It examines the market size and outlook for each technology by region, discusses the advantages and disadvantages of different renewable sources, and assesses the development status and future potential of the renewable energy industry globally. The report also profiles major renewable energy companies and evaluates government policies and industry support programs around the world.
This report provides an overview of the global solar photovoltaic (PV) market. It outlines key industry data like global solar capacity, production figures, and forecasts for future growth. It also examines major country markets and discusses the advantages, challenges, and components of the solar PV industry. The report analyzes factors such as government incentives, technology developments, and manufacturing trends that are shaping the future of the solar industry.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report from GlobalData on clinical trials for abdominal aortic aneurysms. The report provides data on over 100 clinical trials conducted between 2007-2012, including regional breakdown of trials, top sponsoring companies and universities, prominent drugs being tested, and trends in trial enrollment numbers over time. The report aims to give readers an overview of experimental treatments and global research activity for abdominal aortic aneurysms.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
Efficient PHP Development Solutions for Dynamic Web ApplicationsHarwinder Singh
Unlock the full potential of your web projects with our expert PHP development solutions. From robust backend systems to dynamic front-end interfaces, we deliver scalable, secure, and high-performance applications tailored to your needs. Trust our skilled team to transform your ideas into reality with custom PHP programming, ensuring seamless functionality and a superior user experience.
High-Quality IPTV Monthly Subscription for $15advik4387
Experience high-quality entertainment with our IPTV monthly subscription for just $15. Access a vast array of live TV channels, movies, and on-demand shows with crystal-clear streaming. Our reliable service ensures smooth, uninterrupted viewing at an unbeatable price. Perfect for those seeking premium content without breaking the bank. Start streaming today!
https://rb.gy/f409dk
Enhancing Adoption of AI in Agri-food: IntroductionCor Verdouw
Introduction to the Panel on: Pathways and Challenges: AI-Driven Technology in Agri-Food, AI4Food, University of Guelph
“Enhancing Adoption of AI in Agri-food: a Path Forward”, 18 June 2024
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART KALYAN CHART
The Most Inspiring Entrepreneurs to Follow in 2024.pdfthesiliconleaders
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
During the budget session of 2024-25, the finance minister, Nirmala Sitharaman, introduced the “solar Rooftop scheme,” also known as “PM Surya Ghar Muft Bijli Yojana.” It is a subsidy offered to those who wish to put up solar panels in their homes using domestic power systems. Additionally, adopting photovoltaic technology at home allows you to lower your monthly electricity expenses. Today in this blog we will talk all about what is the PM Surya Ghar Muft Bijli Yojana. How does it work? Who is eligible for this yojana and all the other things related to this scheme?
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
Presentation by Herman Kienhuis (Curiosity VC) on Investing in AI for ABS Alu...Herman Kienhuis
Presentation by Herman Kienhuis (Curiosity VC) on developments in AI, the venture capital investment landscape and Curiosity VC's approach to investing, at the alumni event of Amsterdam Business School (University of Amsterdam) on June 13, 2024 in Amsterdam.
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
The Worldwide Market for Cancer Diagnostics, 4th Edition
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
The Worldwide Market for Cancer Diagnostics, 4th Edition
Published on April 2010
Report Summary
"Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound.
Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue
microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And
new entrants have entered the field.
These changes and more are addressed in Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th. Edition. This
report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their
use in cancer diagnostics:
Histology/Cytology
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics
are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing
disease monitoring as treatable cancer enters the realm of the chronic disease.
Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an
exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:
Immunoassay Lab Based Cancer Test Sales
Pap Smear Testing Volumes
World Cancer Statistics
POC Tests
DNA Reagents for Cancer Testing
CTC Testing Markets
Biochip Innovations
New Companies with Novel Approaches
""Laggard"" Companies Who Have Not Met Expectations
Major Protein and Molecular Markers Used in Tissue Staining
Biomarkers Under Investigation
Acquisitions and Mergers
Status of PGx Testing
Microarray Markets in Clinical Labs
Lists of Vendors and Major Products
Unmet Needs of the Marketplace
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 1/16
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori,
IHC, ISH
As well as tests for specific cancers:
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer
This latest edition of Kalorama Information's study takes a fresh look at all of these developments both qualitatively and quantitatively.
The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:
Tests for specific cancers, and
Cancer tests in specific IVD segments This allows the reader to match his or her own situation to the market at large.
In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company
profiles.
Top Tier Companies
Abbott Diagnostics
Beckman Coulter Inc.
Becton, Dickinson and Company (BD)
bioMerieux Inc.
Bio-Rad Laboratories Inc.
Dako A/S
Fujirebio Diagnostics, Inc.
Gen-Probe Inc.
Hologic, Inc.
Inverness Medical Innovations
Ortho Clinical Diagnostics
QIAGEN N.V.
Roche Diagnostics
Siemens Medical Solutions Diagnostics
Sysmex Corporation
Status Quo Leader Companies
AdnaGen AG
Agendia BV
AMDL Diagnostics, Inc. (ADI)
American Diagnostica Inc.
Aperio Technologies, Inc.
Asuragen, Inc.
AviaraDx
Binding Site (The) Ltd.
BioCurex Inc.
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 2/16
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
BioGenex Laboratories, Inc.
BioImagene
Bio-Reference Laboratories, Inc.
Biotage AB
bioTheranostics
BioView Ltd.
Celera Diagnostics
China Medical Technologies, Inc.
Cisbio Bioassays
Clarient Inc. (formerly ChromaVision)
Clinical Data, Inc.
CytoCore, Inc.
DxS Ltd.
Epigenomics AG
Genetix Applied Imaging
Genomic Health, Inc.
Genzyme Genetics
Health Discovery Corporation
HistoRx, Inc.
Ikonisys, Inc.
Ipsogen SA
Lab21 Healthcare
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies
Monogram Biosciences, Inc.
mtm laboratories AG
Myriad Genetics, Inc.
Nanosphere, Inc.
OncoVista Innovative Therapies, Inc.
Pathwork Diagnostics
Precision Therapeutics
Prometheus Laboratories Inc.
Quest Diagnostics
Response Genetics, Inc.
Rosetta Genomics Ltd.
Sequenom
Transgenomic Inc.
Veridex, LLC
Vermillion Inc.
Zila, Inc.
New Entrants
20/20 GeneSystems, Inc.
454 Life Sciences Corporation
Acrometrix Corporation (Life Tech.)
Acupath Laboratories, Inc.
Advalytix
Affymetrix, Inc.
Allegro Diagnostics
Althea Technologies, Inc.
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 3/16
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Amorfix Life Sciences Ltd.
Arbor Vita Corporation
ArcticDx Inc.
Arrayit Diagnostics Inc.
AVEO Pharmaceuticals, Inc.
Axela, Inc.
Baypoint Biosystems, Inc.
Biodesix, Inc.
Biologix Diagnostics, LLC
BioMarker Strategies, LLC
Biomoda
BioMosaics
BioProspecting NB, Inc. (BPNBI)
BioServe
Biosystems International SAS (BSI)
BioTrove, Inc.
Cambridge Research & Instrumentation, Inc. (CRi)
Cangen Biotechnologies, Inc.
Caris Diagnostics
Castle Biosciences Inc.
Celerus Diagnostics
Cell Biosciences
CeMines, Inc.
Cepheid
ChromoCure Inc.
Chronix Biomedical Inc.
Clinical Genomics Pty Ltd.
CombiMatrix Molecular Diagnostics (CMDX)
Comprehensive Cancer Cell (CCC) Diagnostics Inc.
Compugen Ltd.
Correlogic Systems, Inc.
CS-Keys, Inc.
deCode Genetics Inc.
DiaGenic ASA
DiagnoCure --
Diagnoplex
Diagnostic Biosystems Company
DNA Direct, Inc.
DexTerity Diagnostics
EDP Biotech Corporation
Epistem Plc
Exact Sciences Corp.
Exiqon A/S
ExonHit Therapeutics
Exosome Diagnostics Inc.
Expression Pathology Inc.
Falcon Genomics, Inc.
FASgen Diagnostics, LLC
Fluxion Biosciences
Foligo Therapeutics, Inc.
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 4/16
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Gastrocor
Genelex Corporation
GeneNews Limited
Genoptix
iKaryos Diagnostics
Illumina
Inostics GmbH
InteRNA Technologies B.V.
Intrinsic Bioprobes Inc.
Invirion Diagnostics, LLC
InVivoScribe Technologies
Iris BioTechnologies Inc.
IRIS International, Inc.
MabCure Inc.
MacroArray Technologies, LLC
MagArray Inc.
Martell Biosystems, Inc.
Med BioGene, Inc. (MBI)
Medical Prognosis Institute
Metabolon, Inc.
Miraculins Inc.
MolecularMD Corp.
Neogenix Oncology, Inc.
NextGen Sciences
Nuvera Biosciences
Olink AB
Oncimmune LLC
OncoMethylome Sciences S.A.
On-Q-ity
Orion Genomics
Oxford BioTherapeutics
Pacific Edge Biotechnology Ltd. (PEB)
Photocure ASA
Power3 Medical Products, Inc.
Prediction Sciences
Predictive Biosciences
PrognosDx Health, Inc.
Provista Life Sciences LLC
Rubicon Genomics, Inc.
Rules-Based Medicine, Inc. (RBM)
Saladax Biomedical, Inc. (SBI)
SensiGen LLC
Sienna Cancer Diagnostics
Signature Genomic Laboratories, LLC
Singulex Inc.
Skyline Diagnostics B.V.
Source MDx
Soar BioDynamics, Ltd.
Strategic Diagnostics Inc.
Synergenz Bioscience Ltd.
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 5/16
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Targeted Molecular Diagnostics (TMD)
Theranostics Health (TH)
TrimGen Corporation
TrovaGene, Inc.
Vitatex Inc.
WaferGen Biosystems, Inc.
Xceed Molecular (formerly MetriGenix Corporation)
Zetiq Technologies Ltd.
The various diagnostic techniques and trends are discussed from the point of view of their present and potential market impact.
Therefore, the report does not provide an in depth discussion of the etiology, physiology and clinical manifestations of cancer except
where an understanding of these areas is required to understand the impact that new and early diagnostics exert on patient care.
Similarly, the report does not describe the technical aspects of the test modalities, for example
All market data is based on factory sales to the end user and not retail pricing or reimbursement payments. For cancer testing, this
means that the actual dollar market - that is what manufacturers earn from the sale of their products is undervalued. This is because
many of the new tests are offered as test services either by the companies that have developed the tests and/or their partners.
Market data is presented in dollar market size for categories of tests, and for specific analytes where possible. Here the dollar value
of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally
buried in the per test price.
The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally,
current products and technologies establish the standard of care and its value to payers. Many of the assays and imaging techniques
presented in the report are expected to replace the standard of care in 2010, but with healthcare systems' emphasis on cost/benefit
analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.
The information presented in this report is derived on publicly available information sources such as company, government, and
medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and
interviews with industry professionals and experts in the areas of in vitro diagnostics, imaging industries and cancer specialists."
Table of Content
CHAPTER ONE: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Test Segments
Geographic Distribution
Market Trends
Death Rates
Revolutionary Therapeutics
Physician Factor
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 6/16
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Consumer Lobby
Price
CHAPTER TWO: Introduction
Background
Pharmacogenomics
Test Service Commercialization
Cancer - Diagnosis and Therapy Management
Point of View
CHAPTER THREE: Market Trends In The Commercialization Of Cancer Diagnostics
Background
Demographics of Cancer, a Global Phenomenon
Cancer Testing in the World:
Screening and Government Supported Programs
United States of America
International
Europe
Mexico
China
India
Reimbursement and Commercialization of Novel Tests
Test Services - Route for Cancer Innovation
Table 3-3
Regulatory requirements of new products
Strategic Alliances and Partnerships
Personalized Medicine Advances
Gene Patents and Test Commercialization
CHAPTER FOUR: Technological Trends
Background
Biomarker Revolution
The promise of Personalized Medicine
Miniaturization and Multiplexed Biological Assays
The emergence of non-invasive tools
New Technologies Applied To Cancer Diagnostics
Overview
New Platforms
Mass Spectrometry
Chromosome Analysis
Next-Generation Sequencing
RNA - Ribonucleic Acid
The In Vitro/In Vivo Mix
CHAPTER FIVE: Market Analysis
Background
World Regional Segments of the Market for Cancer Diagnostics
Companies and Products
Has Screening Lost its Allure'
Cancer Specific Tests
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 7/16
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Lung Cancer
Ovarian Cancer
Prostate Cancer
CHAPTER SIX: Cancer Tests in IVD Segments (Segment Analysis)
Cancer Diagnostics and IVD Markets
The Market For Cancer Tests In Clinical Chemistry
The Market For Immunoassay Cancer Tests, Lab & Rapid
Point-of-care
The Market for Cancer Tests in Histology / Cytology
Traditional Tissue Stains
Pap Smear and HPV Testing
IHC/ISH
The Market for Tissue Microarrays
The Market For Cancer Tests in Flow Cytometry
The Market for Circulating Tumor Cells in Cancer Diagnostics
The Market For Cancer Molecular Assays
The Market For Cancer Tests in Pharmacodiagnostics
The market for Biochips and Arrays in Cancer Diagnostics
The Commercial Outlook for Cancer Diagnostics
CHAPTER SEVEN: Conclusions
Conclusions and Strategic Implications
Conclusion 1
Implication:
Conclusion 2
Implication:
Conclusion 4
Implication
Conclusion 5
Implication:
Conclusion 6:
Unmet Market Needs
Unmet Need #1
Unmet Need #2
Unmet Need #3
CHAPTER EIGHT: The Top Tier of IVD Companies and their investment in cancer diagnostics
Abbott Diagnostics
Molecular Histology
Molecular Diagnostics
Immunoassays
Beckman Coulter Inc
FOB
Flow Cytometry
Becton, Dickinson and Company (BD)
Histology
bioMerieux Inc
Bio-Rad Laboratories Inc
Dako A/S
Fujirebio Diagnostics, Inc
Gen-Probe Inc
Hologic, Inc
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 8/16
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Histology
HPV
Inverness Medical Innovations
Ortho Clinical Diagnostics
QIAGEN N.V
Roche Diagnostics Indianapolis, IN www.roche.com Recent Revenue History ($ million)
Histology
Immunoassays
PCR
Research
Siemens Medical Solutions Diagnostics
Molecular
In Vivo
Sysmex Corporation
CHAPTER NINE: The Status Quo in Cancer Diagnostics
AdnaGen AG
Agendia BV
AMDL Diagnostics, Inc. (ADI)
American Diagnostica Inc
Aperio Technologies, Inc
Asuragen, Inc
AviaraDx
Binding Site (The) Ltd
BioCurex Inc
BioGenex Laboratories, Inc
BioImagene
Bio-Reference Laboratories, Inc
Biotage AB
bioTheranostics
BioView Ltd
Celera Diagnostics
China Medical Technologies, Inc
Cisbio Bioassays
Clarient Inc. (formerly ChromaVision)
Clinical Data, Inc
CytoCore, Inc
DxS Ltd
Epigenomics AG
Genetix Applied Imaging
Genomic Health, Inc
Genzyme Genetics
Health Discovery Corporation
HistoRx, Inc
Ikonisys, Inc
InterGenetics Inc
Ipsogen SA
Lab21 Healthcare
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies
Monogram Biosciences, Inc
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 9/16
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
mtm laboratories AG
Myriad Genetics, Inc
Nanosphere, Inc
OncoVista Innovative Therapies, Inc
Pathwork Diagnostics
Precision Therapeutics
Prometheus Laboratories Inc
Quest Diagnostics
Response Genetics, Inc
Rosetta Genomics Ltd
Sequenom
Transgenomic Inc
Veridex, LLC
Vermillion Inc
Zila, Inc
CHAPTER TEN: New Entrants And Novel Product Developers
20/20 GeneSystems, Inc
454 Life Sciences Corporation
Acrometrix Corporation (Life Tech.)
Acupath Laboratories, Inc
Advalytix
Affymetrix, Inc
Allegro Diagnostics
Althea Technologies, Inc
Amorfix Life Sciences Ltd
Arbor Vita Corporation
ArcticDx Inc
Arrayit Diagnostics Inc
AVEO Pharmaceuticals, Inc
Axela, Inc
Baypoint Biosystems, Inc
Biodesix, Inc
Biologix Diagnostics, LLC
BioMarker Strategies, LLC
Biomoda
BioMosaics
BioProspecting NB, Inc. (BPNBI)
BioServe
Biosystems International SAS (BSI)
BioTrove, Inc
Cambridge Research & Instrumentation, Inc. (CRi)
Cangen Biotechnologies, Inc
Caris Diagnostics
Castle Biosciences Inc
Celerus Diagnostics
Cell Biosciences
CeMines, Inc
Cepheid
ChromoCure Inc
Chronix Biomedical Inc
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 10/16
11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Clinical Genomics Pty Ltd
CombiMatrix Molecular Diagnostics (CMDX)
Comprehensive Cancer Cell (CCC) Diagnostics Inc
Compugen Ltd
Correlogic Systems, Inc
CS-Keys, Inc
deCode Genetics Inc. ---
DiaGenic ASA
DiagnoCure --
Diagnoplex
Diagnostic Biosystems Company
DNA Direct, Inc
DexTerity Diagnostics
EDP Biotech Corporation
Epistem Plc
Exact Sciences Corp
Exiqon A/S
ExonHit Therapeutics
Exosome Diagnostics Inc
Expression Pathology Inc
Falcon Genomics, Inc
FASgen Diagnostics, LLC
Fluxion Biosciences
Foligo Therapeutics, Inc
Gastrocor
Genelex Corporation
GeneNews Limited
Genoptix
iKaryos Diagnostics
Illumina
Inostics GmbH
InteRNA Technologies B.V
Intrinsic Bioprobes Inc
Invirion Diagnostics, LLC
InVivoScribe Technologies
Iris BioTechnologies Inc
IRIS International, Inc
MabCure Inc
MacroArray Technologies, LLC
MagArray Inc
Martell Biosystems, Inc
Med BioGene, Inc. (MBI)
Medical Prognosis Institute
Metabolon, Inc
Miraculins Inc
MolecularMD Corp
Neogenix Oncology, Inc
NextGen Sciences
Nuvera Biosciences
Olink AB
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 11/16
12. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Oncimmune LLC
OncoMethylome Sciences S.A
On-Q-ity
Orion Genomics
Oxford BioTherapeutics
Pacific Edge Biotechnology Ltd. (PEB)
Photocure ASA
Power3 Medical Products, Inc
Prediction Sciences
Predictive Biosciences
PrognosDx Health, Inc
Provista Life Sciences LLC
Rubicon Genomics, Inc
Rules-Based Medicine, Inc. (RBM)
Saladax Biomedical, Inc. (SBI)
SensiGen LLC
Sienna Cancer Diagnostics
Signature Genomic Laboratories, LLC
Singulex Inc
Skyline Diagnostics B.V
Source MDx
Soar BioDynamics, Ltd
Strategic Diagnostics Inc
Synergenz Bioscience Ltd
Targeted Molecular Diagnostics (TMD)
Theranostics Health (TH)
TrimGen Corporation
TrovaGene, Inc
Vitatex Inc
WaferGen Biosystems, Inc
Xceed Molecular (formerly MetriGenix Corporation)
Zetiq Technologies Ltd
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER THREE: MARKET TRENDS
Table 3-1: Participation rates of CRC screening in National Programs and Pilot Studies
Table 3-2: Selected Lab Service Cancer Tests Launched in 2008 & 2009
Table 3-4: Selected acquisitions and mergers, 2008-2009
Table 3-5: Selected Company Alignments for Cancer Diagnostics, 2008-2009
Table 3-6: Selected collaborations Between IVD and Pharmaceutical Companies, 2008-2009
Table 3-7: U.S. Patents for Selected Molecular Test Platforms
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 12/16
13. Find Industry reports, Company profiles
ReportLinker and Market Statistics
CHAPTER FOUR: TECHNOLOGY TRENDS
Table 4-1: Selected Novel Biomarkers Under Investigation
Table 4-2: Selected biochip test and service innovations, 2008-2009
Table 4-3: Selected Innovations in Blood-Based Cancer Diagnostics, 2008-2009
Table 4-4: Selected non-invasive cancer test innovations, 2008-2009
Table 4-5: Selected test platform innovations, 2008-2009
Table 4-6: Selected companies involved in chromosomal analysis of cancer cells
CHAPTER FIVE: MARKET ANALYSIS
Table 5-1: World Cancer Statistics, new cases per year
Table 5-2: World Population, Cancer Patients and Percentage of Cancer Market IVD Statistics, 2005
Table 5-3: World Cancer Test Sales, by Region, 2009-2014
Table 5-4: Revenues of Selected Cancer Testing Companies($MM)
Table 5-5: Selected Underperformers in the Cancer Market, 2008-2009
Table 5-6: Cancer Diagnostics and the Top Tier of IVD Companies
Table 5-7: Selected new histological breast cancer tests, 2008-2009
Table 5-8: Selected Breast Cancer Test Innovations, 2008-2009
Table 5-9: Selected HPV test innovations, 2008-2009
Table 5-10: Selected colon cancer test innovations, 2008-2009
Table 5-11: Selected PGx tests for colon cancer, 2008-2009
Table 5-12: Selected Lung Cancer Innovations, 2008-2009
Table 5-13: Selected Ovarian Cancer Test Innovations, 2008-2009
Table 5-14: Selected Prostate Cancer Test Innovations, 2008-2009
CHAPTER SIX: SEGMENT MARKET ANALYSIS
Table 6-1: Worldwide Market for Selected Cancer In Vitro Diagnostics (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid
Tests, Molecular Assays, Tissue Arrays, CTCs, Pharmacodiagnostics) 2009-2014
Table 6-2: Selected Tissue Function Clinical Chemistry Tests
Table 6-3: Major Players For Clinical Chemistry Analyzers And Reagents
Table 6-4: Selected Innovations in Cancer Immunoassays, 2008-2009
Table 6-5: Cancer Immunoassay Sales, Lab-based, (PSA, CEA, CA 125, AFP, Others), 2009-2014
Table 6-6: Rapid Cancer Test Sales by Test Category (Fecal Occult Blood, PSA H Pylori, NMP22, Other), Worldwide 2009-2014
Table 6-7: Worldwide Histology/Cytology Sales (Traditional Non Pap, Pap, IHC, ISH, Image Cytometry, Tissue Micorarrays)
2009-2014
Table 6-8: Selected Vendors of Traditional Histology Stains
Table 6-9: Selected HPV Tests Innovations, 2008-2009
Table 6-10: Major Protein and Molecular Markers Used in Tissue Staining
Table 6-11: Selected Chromosome-Based Cancer Tests, 2008-2009
Table 6-12: Selected Digital Imaging Innovations, 2008-2009
Table 6-13: Selected Histopathology Innovations, 2008-2009
Table 6-14: Selected Tissue Microarray Products, 2008-2009
Table 6-15: Selected molecular Cancer Test Innovations, 2008-2009
Table 6-16: Selected Cancer PGx Test Innovations, 2008-2009
Table 6-17: Selected Array-Based Cancer Test Innovations, 2008-2009
Table 6-18: Technology Penetration Forecast for Cancer IVDs 2005-2025 (Minor Role, Moderate Role, Major Role, Rarely Used)
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 13/16
14. Find Industry reports, Company profiles
ReportLinker and Market Statistics
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 14/16
15. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
The Worldwide Market for Cancer Diagnostics, 4th Edition
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 4 200.00 Quantity: _____
Site License--USD 8 400.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 15/16
16. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
The Worldwide Market for Cancer Diagnostics, 4th Edition Page 16/16